R&D costs including capital cost select cancer drugs 2017

This statistic shows the total cost of research and development (R&D) including a 7 percent per annum cost of capital for select cancer drugs that were on the market as of 2017. Alexion Pharmaceuticals' drug Eculizumab had a total R&D cost, including capital, of around 1.09 billion U.S. dollars as of 2017. Total R&D costs without the 7 percent of annual cost of capital stood at some 818 million dollars.

Total R&D costs including 7 percent annual cost of capital for select cancer drugs on the market as of 2017 (in million U.S. dollars)

Drug name (company, R&D start date)	Cost in million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

November 2017

More information

Region

United States

Survey time period

as of November 2017

Supplementary notes

This statistic includes only pharmaceutical companies with a single oncologic drug approved by the Food and Drug Administration (FDA). Values are inflation adjusted for 2017 U.S. dollars.
* Alexion later had two drug approvals in the last quarter of 2015; these drugs are not included in this statistic.
** Compound acquired by the company on this date.

Citation formats